Baird Reiterates an 'Outperform' on Regeneron Pharma (REGN); EYLEA Train Keeps On Rollin'....Raising Numbers Again
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $803.48 --0%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 12
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 12
Join SI Premium – FREE
Baird reiterates an 'Outperform' on Regeneron Pharma (NASDAQ: REGN), price target raised $10 to $120.00.
Baird analyst says, "We are again raising our EYLEA revenue estimates in light of new FY12 guidance (to $315 mln) -- which has essentially doubled from early-January -- and continued robust demand dynamics. As is typically the case in biotech, stocks tend to work as Street estimates are rising, and we fully expect EYLEA numbers to continue to go up as a result of today's update. Following that logic, we now think shares can work into the $120-range near-term."
Baird raises FY12 EPS estimate from (0.89) to $0.28
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $102.08 yesterday.
Baird analyst says, "We are again raising our EYLEA revenue estimates in light of new FY12 guidance (to $315 mln) -- which has essentially doubled from early-January -- and continued robust demand dynamics. As is typically the case in biotech, stocks tend to work as Street estimates are rising, and we fully expect EYLEA numbers to continue to go up as a result of today's update. Following that logic, we now think shares can work into the $120-range near-term."
Baird raises FY12 EPS estimate from (0.89) to $0.28
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $102.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Phillip Securities Downgrades Shopify (SHOP) to Accumulate
- Chardan Starts Odysight.AI Inc. (ODYS) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
